A closer look at “IGTP and Blood and Tissue Bank Advance Clinical-Grade Extracellular Vesicle Manufacturing”, exactly as the source publishes it. Researchers at the Germans Trias i Pujol Research Institute (IGTP) and the Blood and Tissue Bank (BST) have validated a semiautomated platform for producing extracellular vesicles (EVs) that meets pharmaceutical quality standards. The system delivers consistent batches, overcoming a major hurdle in The system delivers consistent batches, overcoming a major hurdle in translating EV-based therapies from lab to clinic. Extracellular vesicles are emerging as promising tools for regenerative medicine, but manufacturing variability has limited their therapeutic use.
This new platform ensures reproducibility and scalability, key requirements for regulatory approval and clinical trials. The collaboration between IGTP and BST highlights how partnerships between research institutes and tissue banks can accelerate biomedical innovation. By standardizing production, the team is paving the way for future applications in tissue repair and disease treatment. This listing links straight to the original page, where the content is available in full.